 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 May 2000 | Volume 132 Issue 10 | Pages 810-819
Purpose: To evaluate the accuracy of conventional and new methods of Papanicolaou (Pap) testing when used to detect cervical cancer and its precursors.
Data Sources: Systematic search of English-language literature through October 1999 using MEDLINE, EMBASE, other computerized databases, and hand searching.
Study Selection: All studies that compared Pap testing (conventional methods, computer screening or rescreening, or monolayer cytology) with a concurrent reference standard (histologic examination, colposcopy, or cytology).
Data Extraction: Two reviewers independently reviewed selection criteria and completed 2 x 2 tables for each study.
Data Synthesis: 94 studies of the conventional Pap test and three studies of monolayer cytology met inclusion criteria. No studies of computerized screening were included. Data were organized by cytologic and histologic thresholds used to define disease. For conventional Pap tests, estimates of sensitivity and specificity varied greatly in individual studies. Methodologic quality and frequency of histologic abnormalities also varied greatly between studies. In the 12 studies with the least biased estimates, sensitivity ranged from 30% to 87% and specificity ranged from 86% to 100%.
Conclusions: Insufficient high-quality data exist to estimate test operating characteristics of new cytologic methods for cervical screening. Future studies of these technologies should apply adequate reference standards. Most studies of the conventional Pap test are severely biased: The best estimates suggest that it is only moderately accurate and does not achieve concurrently high sensitivity and specificity. Cost-effectiveness models of cervical cancer screening should use more conservative estimates of Pap test sensitivity.
Author and Article Information
From Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, North Carolina.
Disclaimer: This article is based on an evidence report prepared by Duke University under contract with the Agency for Healthcare Research and Quality (AHRQ contract 290-97-0014). The authors are responsible for its content, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Acknowledgments: The authors thank Jean Slutsky of the Agency for Healthcare Research and Quality for overall project guidance, Jane Kolimaga for organization and management of the project, Ruth Goslin and Rebecca Gray for assistance with manuscript preparation, and the Advisory Panel and peer reviewers of the Evidence Report for many helpful suggestions throughout the entire process.
Grant Support: Dr. Nanda was a Veterans Affairs Women's Health Fellow at the Durham Veterans Affairs Medical Center while conducting this study.
Requests for Single Reprints: Kavita Nanda, MD, MHS, Clinical Research Department, Family Health International, Box 13950, Research Triangle Park, NC 27709; e-mail, knanda{at}fhi.org.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Nanda: Clinical Research Department, Family Health International, Box 13950, Research Triangle Park, NC 27709.
Drs. McCrory and Matchar: Center for Clinical Health Policy Research, Duke University Medical Center, First Union Tower, 2200 West Main Street, Suite 230, Durham, NC 27705.
Dr. Myers: Department of Obstetrics and Gynecology, Box 3279 Medical Center, Duke University Medical Center, Durham, NC 27710.
Dr. Bastian: Health Services Research and Development (152), Durham Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC 27705.
Dr. Hasselblad: Department of Community and Family Medicine, Box 3850 Medical Center, Duke University Medical Center, Durham, NC 27710.
Mr. Hickey: School of Medicine, Duke University, Durham, NC 27710. REVIEW
Accuracy of the Papanicolaou Test in Screening for and Follow-up of Cervical Cytologic Abnormalities
A Systematic Review
This article has been cited by other articles:
|
|
 |
|
  A. G. Siebers, P. J.J.M. Klinkhamer, M. Arbyn, A. O. Raifu, L. F.A.G. Massuger, and J. Bulten Cytologic Detection of Cervical Abnormalities Using Liquid-Based Compared With Conventional Cytology: A Randomized Controlled Trial Obstet. Gynecol., December 1, 2008; 112(6): 1327 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Stout, J. D. Goldhaber-Fiebert, J. D. Ortendahl, and S. J. Goldie Trade-offs in Cervical Cancer Prevention: Balancing Benefits and Risks Arch Intern Med, September 22, 2008; 168(17): 1881 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Chin-Hong, J. M. Berry, S.-C. Cheng, J. A. Catania, M. D. Costa, T. M. Darragh, F. Fishman, N. Jay, L. M. Pollack, and J. M. Palefsky Comparison of Patient- and Clinician-Collected Anal Cytology Samples to Screen for Human Papillomavirus-Associated Anal Intraepithelial Neoplasia in Men Who Have Sex with Men Ann Intern Med, September 2, 2008; 149(5): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Blatter and B. J. Monk The Pediatrician's Role in Preventing Cervical Cancer Clinical Pediatrics, September 1, 2008; 47(7): 627 - 638. [PDF]
|
|
|
|
 |
|
 M. Jit, Y. H. Choi, and W J. Edmunds Economic evaluation of human papillomavirus vaccination in the United Kingdom BMJ, July 17, 2008; 337(jul17_2): a769 - a769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Monsonego, G. Pollini, M. J. Evrard, P. Sednaoui, L. Monfort, D. Quinzat, R. Dachez, and K. Syrjanen Linear array genotyping and hybrid capture II assay in detecting human papillomavirus genotypes in women referred for colposcopy due to abnormal Papanicolaou smear Int J STD AIDS, June 1, 2008; 19(6): 385 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L Franco Human Papillomavirus and Cervical Cancer: Integrating the New Prevention Strategies Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 367 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Runowicz Molecular Screening for Cervical Cancer -- Time to Give up Pap Tests? N. Engl. J. Med., October 18, 2007; 357(16): 1650 - 1653. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kim, K. M. Kuntz, N. K. Stout, S. Mahmud, L. L. Villa, E. L. Franco, and S. J. Goldie Multiparameter Calibration of a Natural History Model of Cervical Cancer Am. J. Epidemiol., July 15, 2007; 166(2): 137 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ronco, J. Cuzick, P. Pierotti, M. P. Cariaggi, P. D. Palma, C. Naldoni, B. Ghiringhello, P. Giorgi-Rossi, D. Minucci, F. Parisio, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial BMJ, July 7, 2007; 335(7609): 28 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Franzmann, E. P. Reategui, F. Pedroso, F. G. Pernas, B. M. Karakullukcu, K. L. Carraway, K. Hamilton, R. Singal, and W. J. Goodwin Soluble CD44 Is a Potential Marker for the Early Detection of Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1348 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Bock and B. M. Kwan Encouragement of Patient Self-management and Adherence through Use of a Computerized Tracking System for Cervical and Colon Cancer Screening J Am Board Fam Med, May 1, 2007; 20(3): 316 - 319. [Full Text] [PDF]
|
|
|
|
|
|
N. Van de Velde, M. Brisson, and M.-C. Boily Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am. J. Epidemiol., April 1, 2007; 165(7): 762 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Steinau, M. S. Rajeevan, D. R. Lee, M. T. Ruffin, I. R. Horowitz, L. C. Flowers, T. Tadros, G. Birdsong, M. Husain, D. C. Kmak, et al. Evaluation of RNA Markers for Early Detection of Cervical Neoplasia in Exfoliated Cervical Cells Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 295 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kjaer, E. Hogdall, K. Frederiksen, C. Munk, A. van den Brule, E. Svare, C. Meijer, A. Lorincz, and T. Iftner The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus-Positive, Cytologically Normal Women Over a 10-Year Period Cancer Res., November 1, 2006; 66(21): 10630 - 10636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Kulasingam, E. R. Myers, H. W. Lawson, K. J. McConnell, K. Kerlikowske, J. Melnikow, A. E. Washington, and G. F. Sawaya Cost-effectiveness of Extending Cervical Cancer Screening Intervals Among Women With Prior Normal Pap Tests Obstet. Gynecol., February 1, 2006; 107(2): 321 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Legood, A. Gray, J. Wolstenholme, and S. Moss Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies BMJ, January 14, 2006; 332(7533): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A Kahn, D I Bernstein, S L Rosenthal, B Huang, L M Kollar, J L Colyer, A M Tissot, P A Hillard, D Witte, P Groen, et al. Acceptability of human papillomavirus self testing in female adolescents Sex Transm Inf, October 1, 2005; 81(5): 408 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G S Ogilvie, D M Patrick, M Schulzer, J W Sellors, M Petric, K Chambers, R White, and J M FitzGerald Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis Sex Transm Inf, June 1, 2005; 81(3): 207 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Harris, R. D. Burk, J. M. Palefsky, L. S. Massad, J. Y. Bang, K. Anastos, H. Minkoff, C. B. Hall, M. C. Bacon, A. M. Levine, et al. Incidence of Cervical Squamous Intraepithelial Lesions Associated With HIV Serostatus, CD4 Cell Counts, and Human Papillomavirus Test Results JAMA, March 23, 2005; 293(12): 1471 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Franzmann, E. P. Reategui, K. L. Carraway, K. L. Hamilton, D. T. Weed, and W. J. Goodwin Salivary Soluble CD44: A Potential Molecular Marker for Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 735 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Anhang, A. Goodman, and S. J. Goldie HPV Communication: Review of Existing Research and Recommendations for Patient Education CA Cancer J Clin, September 1, 2004; 54(5): 248 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Kulmala, S. Syrjanen, I. Shabalova, N. Petrovichev, V. Kozachenko, J. Podistov, O. Ivanchenko, S. Zakharenko, R. Nerovjna, L. Kljukina, et al. Human Papillomavirus Testing with the Hybrid Capture 2 Assay and PCR as Screening Tools J. Clin. Microbiol., June 1, 2004; 42(6): 2470 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Kahn Self-testing for human papillomavirus using a vaginal swab: placing prevention of cervical cancer in the patient's hands Ann. Onc., June 1, 2004; 15(6): 847 - 849. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Widschwendter, C. Gattringer, L. Ivarsson, H. Fiegl, A. Schneitter, A. Ramoni, H. M. Muller, A. Wiedemair, S. Jerabek, E. Muller-Holzner, et al. Analysis of Aberrant DNA Methylation and Human Papillomavirus DNA in Cervicovaginal Specimens to Detect Invasive Cervical Cancer and Its Precursors Clin. Cancer Res., May 15, 2004; 10(10): 3396 - 3400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Goldie, M. Kohli, D. Grima, M. C. Weinstein, T. C. Wright, F. X. Bosch, and E. Franco Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine J Natl Cancer Inst, April 21, 2004; 96(8): 604 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, J. J. Kim, and T. C. Wright Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or More Obstet. Gynecol., April 1, 2004; 103(4): 619 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Sawaya, K. J. McConnell, S. L. Kulasingam, H. W. Lawson, K. Kerlikowske, J. Melnikow, N. C. Lee, G. Gildengorin, E. R. Myers, and A. E. Washington Risk of Cervical Cancer Associated with Extending the Interval between Cervical-Cancer Screenings N. Engl. J. Med., October 16, 2003; 349(16): 1501 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ferreccio, M. C. Bratti, M. E. Sherman, R. Herrero, S. Wacholder, A. Hildesheim, R. D. Burk, M. Hutchinson, M. Alfaro, M. D. Greenberg, et al. A Comparison of Single and Combined Visual, Cytologic, and Virologic Tests as Screening Strategies in a Region at High Risk of Cervical Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Kulasingam and E. R. Myers Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs JAMA, August 13, 2003; 290(6): 781 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.B. Lipton, D. Dodick, R. Sadovsky, K. Kolodner, J. Endicott, J. Hettiarachchi, and W. Harrison A self-administered screener for migraine in primary care: The ID MigraineTM validation study Neurology, August 12, 2003; 61(3): 375 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Wright Jr. Chapter 10: Cervical Cancer Screening Using Visualization Techniques J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 66 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Sherman Chapter 11: Future Directions in Cervical Pathology J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Franco Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. F. Belch, E. J. Topol, G. Agnelli, M. Bertrand, R. M. Califf, D. L. Clement, M. A. Creager, J. D. Easton, J. R. Gavin III, P. Greenland, et al. Critical Issues in Peripheral Arterial Disease Detection and Management: A Call to Action Arch Intern Med, April 28, 2003; 163(8): 884 - 892. [Full Text] [PDF]
|
|
|
|
|
|
J. Coste, B. Cochand-Priollet, P. de Cremoux, C. Le Gales, I. Cartier, V. Molinie, S. Labbe, M.-C. Vacher-Lavenu, and P. Vielh Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening BMJ, April 5, 2003; 326(7392): 733 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Sherman, S. S. Wang, R. Tarone, L. Rich, and M. Schiffman Histopathologic Extent of Cervical Intraepithelial Neoplasia 3 Lesions in the Atypical Squamous Cells of Undetermined Significance Low-grade Squamous Intraepithelial Lesion Triage Study: Implications for Subject Safety and Lead-time Bias Cancer Epidemiol. Biomarkers Prev., April 1, 2003; 12(4): 372 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Sherman, A. T. Lorincz, D. R. Scott, S. Wacholder, P. E. Castle, A. G. Glass, I. Mielzynska-Lohnas, B. B. Rush, and M. Schiffman Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort Analysis J Natl Cancer Inst, January 1, 2003; 95(1): 46 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, L. Gaffikin, K. K. Limpahayom, P. Lumbiganon, S. Warakamin, J. King, B. Yi, P. Ringers, and P. D. Blumenthal Costs and Benefits of Different Strategies to Screen for Cervical Cancer in Less-Developed Countries J Natl Cancer Inst, October 2, 2002; 94(19): 1469 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Larry Maxwell, J. W. Carlson, M. Ochoa, T. Krivak, G. S. Rose, and E. R. Myers Costs and Effectiveness of Alternative Strategies for Cervical Cancer Screening in Military Beneficiaries Obstet. Gynecol., October 1, 2002; 100(4): 740 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Mandelblatt, W. F. Lawrence, S. M. Womack, D. Jacobson, B. Yi, Y.-t. Hwang, K. Gold, J. Barter, and K. Shah Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer JAMA, May 8, 2002; 287(18): 2372 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kim, T. C. Wright, and S. J. Goldie Cost-effectiveness of Alternative Triage Strategies for Atypical Squamous Cells of Undetermined Significance JAMA, May 8, 2002; 287(18): 2382 - 2390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Howard, J. Sellors, and A. Lytwyn Cervical intraepithelial neoplasia in women presenting with external genital warts Can. Med. Assoc. J., March 1, 2002; 166(5): 598 - 599. [Full Text] [PDF]
|
|
|
|
 |
|
 A. BARRATT Making the most of Pap tests J Epidemiol Community Health, November 1, 2001; 55(11): 774 - 775. [Full Text] [PDF]
|
|
|
|
|
|
E. L. Franco, E. Duarte-Franco, and A. Ferenczy The merits of new alternatives to the Papanicolaou test Can. Med. Assoc. J., September 1, 2001; 165(6): 739 - 740. [Full Text]
|
|
|
|
|
|
S. J. Goldie, L. Kuhn, L. Denny, A. Pollack, and T. C. Wright Policy Analysis of Cervical Cancer Screening Strategies in Low-Resource Settings: Clinical Benefits and Cost-effectiveness JAMA, June 27, 2001; 285(24): 3107 - 3115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Sawaya, A. D. Brown, A. E. Washington, and A. M. Garber Current Approaches to Cervical-Cancer Screening N. Engl. J. Med., May 24, 2001; 344(21): 1603 - 1607. [Full Text] [PDF]
|
|
|
|
|
|
E. R. MYERS, D. C. MCCRORY, S. SUBRAMANIAN, N. MCCALL, K. NANDA, S. DATTA, and D. B. MATCHAR Setting the Target for a Better Cervical Screening Test: Characteristics of a Cost-Effective Test for Cervical Neoplasia Screening Obstet. Gynecol., November 1, 2000; 96(5): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Nurs., October 1, 2000; 3(4): 106 - 112. [Full Text]
|
|
Article
